Aldose reductase gene expression is increased in diabetic nephropathy

Journal of Clinical Endocrinology and Metabolism

Volumn 82, Issue 7, 1997, Pages 2294-2298

  Shah, V O ^a   Dorin, R I ^b   Sun, Y ^a   Braun, M ^a   Zager, P G ^a  

^a UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^b VA Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE REDUCTASE; GLYCOSYLATED HEMOGLOBIN;

ADULT; AGED; ARTICLE; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION REGULATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK FACTOR;

ACTINS; ADULT; AGE FACTORS; AGED; ALDEHYDE REDUCTASE; ANALYSIS OF VARIANCE; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; MALE; MIDDLE AGED; RNA, MESSENGER; SEX FACTORS;

EID: 0030854820     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.82.7.2294     Document Type: Article

References (46)

1. Friedman EA. 1982 Diabetic nephropathy: strategies in prevention and management. Kidney Int. 21:780-791.
2. Seaquist E, Goetz F, Barbosa J, Rich S. 1987 Evidence for genetic susceptibility to diabetic nephropathy. Diabetes. 36:(Suppl 1)105A.
3. Krolewski AS, Warram JH, Rand LI, Kahn CR. 1987 Epidemiologic approach to the etiology of type 1 diabetes mellitus and its complications [Review]. N Engl J Med. 317:1390-1398.
4. Seaquist ER, Goetz FC, Rich S, Barbosa J. 1989 Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med. 320:1161-1165.
5. Krolewski AS, Doria A, Magre J, Warram JH, Housman D. 1992 Molecular genetic approaches to the identification of genes involved in the development of nephropathy in insulin-dependent diabetes mellitus. J Am Soc Nephrol. 3:S9-S17.
6. Foster DW. 1994 Diabetes mellitus: Harrison's principles of internal medicine. New York: McGraw-Hill, 1979-1999.
7. Andersen AR, Christiansen JS, Andersen JK, Kreiner S, Deckert T. 1983 Diabetic nephropathy in type 1 diabetes: an epidemiological study. Diabetologia. 25:496-501.
8. Kofoed-Enevoldsen A, Borch-Johnsen K, Kreiner S, Nerup J, Deckert T. 1987 Declining incidence of persistent proteinuria in type 1 (insulin-dependent) diabetic patients in Denmark. Diabetes. 36:205-209.
9. Krolewski AS, Warram JH, Chriestlieb AR, Busick EJ, Kahn CR. 1985 The changing natural history of nephropathy in type 1 diabetes. Am J Med. 78:785-794.
10. Nelson RG, Knowler WC, Pettitt DJ, Saad MF, Bennett PH. 1993 Diabetic kidney disease in Pima Indians. Diabetes Care. 16:335-341.
11. Eggers PW, Connerton R, McMullan M. 1984 The Medicare experience with end-stage renal disease: Trends in incidence, prevalence and survival. Health Care Fin Rev. 5:69-70.
12. Bekhor I, Shi S, Unakar J. 1990 Aldose reductase m-RNA is an epithelial cell-specific gene transcript in both normal and cataractous rat lens. Invest Ophtal Vis Sci. 31:1876-1885.
13. Carper D, Kaneko M, Stark H, Hohman T. 1990 Increase in aldose reductase m-RNA in dog lens epithelial cells under hypertonic conditions. Exp Eye Res. 50:743.
14. Ludvigson MA, Sorenson RL. 1980 Immunohistochemical localization of aldose reductase. Diabetes. 29:450.
15. Nishimura C, Graham C, Hohman TC, et al. 1988 Characterization of mRNA and genes for aldose reductase in rat. Biochem Biophys Res Commun. 153:1051-1059.
16. Kikkawa R, Umemura K, Haneda M, Arimura T, Ebata K, Shigeta Y. 1987 Evidence for existence of polyol pathway in cultured rat mesangial cells. Diabetes. 36:240.
17. Kinoshita JH. 1965 Cataracts in galactosemia. Invest Ophthalmol. 4:786.
18. Robinson Jr WG, Kador PF, Kinoshita JH. 1983 Retinal capillaries: basement membrane thickening by galactosemia prevented with aldose reductase inhibitor. Science. 221:1177.
19. Kinoshita JH, Fukushi S, Kador P, Merola LO. 1979 Aldose reductase in diabetic complications of the eye. Metabolism. 28:462.
20. Gabbay KH. 1973 Role of sorbitol pathway in neuropathy. Adv Metab Disord 2(Suppl 2):417.
21. Bank N, Coco M, Aynedjian HS. 1989 Galactose feeding causes glomerular hyperperfusion: prevention by aldose reductase inhibitors. Am J Physiol. 256:F994.
22. Bank N, Mower P, Aynedjian HS, et al. 1989 Sorbinil prevents glomerular hyperperfusion in diabetic rats. Am J Physiol. 256:F1000.
23. Goldfarb S, Simmons DA, Kern EFO. 1986 Amelioration of glomerular hyperfiltration in acute experimental diabetes mellitus by dietary myo-inusitol supplementation and aldose reductase inhibition. Trans Assoc Am Physicians. 199:67.
24. Bondy C, Cowley Jr BD, Lightman SL, Kador PF. 1990 Feedback inhibition of aldose reductase gene expression in rat renal medulla. J Clin Invest. 86:1103.
25. Dorin RI, Shah VO, Kaplan D, Vela S, Zager PG. 1995 Regulation of aldose reductase gene expression in renal cortex and medulla of rats. Diabetologia. 38:46-54.
26. Zager PG, Dorin RI, Shah VO, et al. 1993 Aldose reductase expression and prostaglandin E2 production are coordinately regulated in cultured rat mesangial cells. Metabolism. 42:269-276.
27. Kaneko M, Carper D, Nishimura C, Millen J, Bock M, Hohman TC. 1990 Induction of aldose reductase expression in rat kidney mesangial cells and Chinese hamster ovary cells under hypertonic conditions. Exp Cell Res. 188:135.
28. Dent MT, Tebbs SE, Gonzalez AM, Ward JD, Wilson RM. 1994 Neutrophil aldose reductase activity and its association with established diabetic microvascular complications. Diabetic Med. 8:439-442.
29. Hamada Y, Kitoh R, Raskin P. 1991 Increased activity of erythrocyte aldose reductase in insulin-dependent diabetes with severe diabetic complications. Diabetes. 40(Suppl 1):9A.
30. Nishimura C, Saito T, Ito T, Omori Y, Tanimoto T. 1994 High levels of erythrocyte aldose reductase and diabetic retinopathy in NIDDM patients. Diabetologia. 37:328-330.
31. Ratliff DM, Vander Jagt DJ, Eaton RP, Vander Jagt DL. 1996 Increased levels of methylglyoxal-metabolizing enzyme in mononuclear and polymorphonuclear cells from IDDM with complications: aldose reductase, glyoxalase I and glyoxalase II-a clinical research center study. J Clin Endocrinol Metab. 81:488-492.
32. Abbott Laboratories. 1994 Package insert. North Chicago: Abbott Laboratories.
33. Boehringer Mannheim. 1993 R1 catalog 1f27632 or 7474015, R2 catalog 1127659 for the quantitative determination of creatinine in serum, plasma, and urine. Indianapolis: Boehringer Mannheim.
34. Boehringer Mannheim. 1993 Catalog 935000, application code 171, for the quantitative determination of protein in urine and cerebrospinal fluid. Indianapolis: Boehringer Mannheim.
35. n dinucleotide repeat polymorphic marker at the 5′ end of the AR gene is associated with early-onset diabetic retinopathy in NIDDM patients. Diabetes. 44:727-734.
36. Sun Y, Shah V, Nikolic J, Jones M, Griffith J, Dorin R, Zager P. 1996 Variability in the structure and expression of the aldose reductase gene modulates the risk for DN. J Am Soc Nephrol. 7:1366.
37. Heesom A, Hibberd M, Millward A, Demaine A. 1997 Polymorphism in the 5′-end of the AR gene is strongly associated with the development of diabetic nephropathy in type 1 diabetes. Diabetes. 46:287-291.
38. Yagihashi S, Yamaoka T, Nishimura C, Yamagishi S, Sugimoto K, Kokai Y. Establishment of mice transgenic for human aldose reductase: characterization and effects of galactose feeding. Proc of the 53rd Annual Meet of the Am Diabetes Assoc. 1993. (Abstract 361).
39. Lee AYW, Chung SK, Chung SSM. 1995 Demonstration that polyol accumulation is responsible for diabetic cataract by the use of trangenic mice expressing the aldose reductase gene in the lens. Proc Natl Acad Sci USA. 92:2780-2784.
40. Yamoka T, Nishimura C, Yamashita K, et al. 1995 Acute onset of diabetic pathological changes in trangenic mice with human aldose reductase c-DNA. Diabetologia. 38:255-261.
41. Tilton RG, Chang K, Pugliese G, et al. 1989 Prevention of hemodynamic and vascular albumin filtration changes in diabetic rats by aldose reductase inhibitors. Diabetes. 38:1258.
42. Byer-Mears A, Ku L, Cohen MP. 1984 Glomerular polyol accumulation in diabetes and its prevention by oral sorbini. Diabetes 33:604.
43. Itagaki I, Shimizu K, Kamanaka Y, et al. 1994 The effect of aldose reductase inhibitor (Epalrestat) on diabetic nephropathy in rats. Diabetes Res Clin Pract. 25:147-154.
44. Cunningham JJ, Mearkle PL, Brown RG. Vitamin C. 1994 An aldose reductase inhibitor that normalizes erythrocyte sorbitol in insulin-dependent diabetes mellitus. J Am Coll Nutr. 13:344-350.
45. Pedersen M, Christiansen JS, Mogensen CE. 1991 Reduction of glomerular hyperfiltration in normoalbuminic IDDM patients by six months of aldose reductase inhibition. Diabetes. 40:527-531.
46. Passariello N, Depe J, Marazzo G, et al. 1993 Effect of aldose reductase inhibitor (tolrestat) on urinary albumin excretion rate and glomerular filtration rate in IDDM subjects with nephropathy. Diabetes Care. 16:789-795.